Have a feature idea you'd love to see implemented?
Let us know!
CSBR Champions Oncology Inc
Price (delayed)
$7.87
Market cap
$108.76M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.05
Enterprise value
$112.78M
Champions Oncology is a data-driven research organization that leverages an oncology research center of excellence to develop transformative technology and accelerate oncology research and development. This technology ranges from computational-based
Highlights
The net income has soared by 94% YoY and by 82% from the previous quarter
The company's EPS has surged by 93% YoY and by 80% QoQ
Key stats
What are the main financial stats of CSBR
Market
Valuations
Earnings
Shares outstanding
13.82M
Market cap
$108.76M
Enterprise value
$112.78M
Price to earnings (P/E)
N/A
Price to book (P/B)
157.1
Price to sales (P/S)
2
EV/EBIT
N/A
EV/EBITDA
98.07
EV/Sales
2.11
Revenue
$53.57M
Gross profit
$23.97M
Net income
-$598,000
EBIT
-$636,000
EBITDA
$1.15M
Free cash flow
-$2.82M
Per share
Balance sheet
Liquidity
EPS
-$0.05
EPS diluted
-$0.06
Free cash flow per share
-$0.21
Book value per share
$0.05
Revenue per share
$3.94
TBVPS
$1.83
Total assets
$25.24M
Total liabilities
$24.56M
Debt
$6.78M
Equity
$681,000
Working capital
-$4.78M
Debt to equity
9.95
Current ratio
0.75
Quick ratio
0.7
Net debt/EBITDA
3.5
Margins
Efficiency
Dividend
EBITDA margin
2.1%
Gross margin
44.7%
Net margin
-1.1%
Operating margin
-1.5%
Return on assets
-2.3%
Return on equity
N/A
Return on invested capital
-7%
Return on capital employed
-10%
Return on sales
-1.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CSBR stock price
How has the Champions Oncology stock price performed over time
Intraday
-2.96%
1 week
22.97%
1 month
72.97%
1 year
57.09%
YTD
40.04%
QTD
61.6%
Financial performance
How have Champions Oncology's revenue and profit performed over time
Revenue
$53.57M
Gross profit
$23.97M
Operating income
-$787,000
Net income
-$598,000
Gross margin
44.7%
Net margin
-1.1%
The net margin has soared by 94% YoY and by 83% QoQ
The net income has soared by 94% YoY and by 82% from the previous quarter
The operating margin has soared by 92% YoY and by 78% from the previous quarter
The company's operating income has surged by 92% YoY and by 77% QoQ
Growth
What is Champions Oncology's growth rate over time
Valuation
What is Champions Oncology stock price valuation
P/E
N/A
P/B
157.1
P/S
2
EV/EBIT
N/A
EV/EBITDA
98.07
EV/Sales
2.11
The company's EPS has surged by 93% YoY and by 80% QoQ
CSBR's P/B is 134% above its 5-year quarterly average of 67.0
The price to sales (P/S) is 54% higher than the last 4 quarters average of 1.3 but 9% lower than the 5-year quarterly average of 2.2
The revenue has grown by 7% YoY and by 3.7% from the previous quarter
Efficiency
How efficient is Champions Oncology business performance
The company's return on sales has surged by 94% YoY and by 82% QoQ
The ROA has soared by 92% YoY and by 82% from the previous quarter
The company's return on invested capital has surged by 92% YoY and by 82% QoQ
Dividends
What is CSBR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CSBR.
Financial health
How did Champions Oncology financials performed over time
The total assets is 2.8% greater than the total liabilities
The total liabilities has contracted by 13% YoY and by 2.8% from the previous quarter
CSBR's quick ratio is up by 13% since the previous quarter and by 11% year-on-year
The debt to equity has soared by 146% from the previous quarter but it has plunged by 89% YoY
The debt fell by 16% YoY and by 4.7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.